MDUFA VI Reauthorization: What It Means for Device Sponsors Through 2032

Every five years, the Medical Device User Fee Amendments quietly reset the operating conditions for every device company doing business with FDA — review timelines, staffing levels, fee structures, and process improvements are all negotiated in a single package. MDUFA VI, covering fiscal years 2028 through 2032, reached agreement in principle in early 2026, and the draft commitment letter released in July gives sponsors their clearest look yet at what’s coming.

How MDUFA Actually Works

Under the Medical Device User Fee and Modernization Act of 2002, industry pays user fees in exchange for FDA’s commitment to measurable review performance goals — timelines for acting on 510(k)s, De Novo requests, and PMAs. Every five years, FDA and industry negotiate a new agreement, memorialized in a commitment letter, which Congress then uses as the foundation for reauthorization legislation. The current program, MDUFA V, expires September 30, 2027; without reauthorization, FDA loses a substantial portion of its device review funding and capacity.

Negotiations for MDUFA VI began in October 2025, and FDA and industry representatives confirmed reaching an agreement in principle in April 2026 — described by industry representatives at the 2026 MedCon conference as occurring on a “record timeline.” FDA posted its draft commitment letter on July 7, 2026, opening a public comment period that closed August 7, with an additional public meeting held August 5 to gather stakeholder input before the agency finalizes the letter and sends it to Congress.

What’s Actually in the Draft Agreement

A new expedited pre-submission track. The draft introduces “Focused Follow-Up Pre-Submissions” — a faster-turnaround mechanism intended for targeted follow-up questions related to a prior pre-submission, with FDA committing to a written response within 45 calendar days of receipt. This addresses a long-standing industry complaint that traditional pre-submission cycles are too slow for iterative, narrowly scoped questions.

Conversion of the TAP pilot into a full program. The Total Product Lifecycle Advisory Program (TAP), previously a pilot, is set to become a permanent program under the draft agreement — expanding the enhanced, proactive FDA engagement model beyond its initial limited scope.

Staffing commitments at CDRH. This may be the single most consequential element for sponsors. CDRH has been operating with roughly 22% fewer staff than it had in 2024, following broader HHS workforce reductions that eliminated approximately 4,400 FDA employees agency-wide. MDUFA VI includes a commitment to hire “substantial numbers of additional review staff,” and industry negotiators specifically pushed for language ensuring funding for MDUFA V-level staffing continues into MDUFA VI — a direct response to the current capacity shortfall’s effect on review timelines.

Real-world evidence provisions. MDUFA VI negotiations included discussions about formalizing RWE-related provisions in the commitment letter, building on FDA’s December 2025 final RWE guidance and potentially creating clearer expectations for how manufacturers use real-world data to support both premarket submissions and post-market obligations.

A continued focus on De Novo and review consistency. Industry stakeholders pushed for changes to the De Novo and pre-submission programs during negotiations, and FDA has signaled it will focus on improving review consistency by targeting one specific review-practice area for improvement each year of the agreement — rather than attempting broad simultaneous reform.

The Timeline Sponsors Should Track

The current program expires September 30, 2027, and the next agreement is expected to run fiscal years 2028 through 2032. FDA must finalize the commitment letter and transmit recommended user fee revenues and performance goals to the House Energy and Commerce Committee and the Senate HELP Committee by January 15, 2027. From there, Congress uses the negotiated package as the basis for reauthorization legislation — historically, MDUFA reauthorizations have been narrower in scope than their drug-user-fee counterparts, with core performance commitments typically carried forward largely unchanged, though Congress retains authority to modify the agreement or attach separate policy provisions.

What This Means for Regulatory Planning Now

Staffing constraints are a near-term reality, not just a negotiating point. Sponsors submitting under the current MDUFA V framework should factor the documented CDRH staffing shortfall into their own timeline expectations now — the reauthorization won’t take effect until FY2028 at the earliest, meaning current review capacity constraints persist through the remainder of MDUFA V.

The Focused Follow-Up Pre-Submission mechanism, once implemented, changes iterative regulatory strategy. Sponsors who currently avoid pre-submission cycles for narrow, follow-up-style questions because of turnaround time should plan to use the new track once available — it’s specifically designed for exactly that use case.

TAP program expansion is worth planning around for complex or first-in-category devices. As TAP moves from pilot to permanent program, sponsors developing genuinely novel technologies should evaluate early engagement through it as part of their premarket strategy, rather than defaulting only to standard pre-submission channels.

RWE strategy and MDUFA VI are converging, not separate workstreams. Given that MDUFA VI negotiations explicitly touched RWE provisions, sponsors building real-world evidence into their regulatory strategy under FDA’s December 2025 guidance should watch the final commitment letter closely for any additional formalized expectations.

MDUFA VI won’t take effect for roughly two more fiscal years, but the negotiation record — staffing commitments, new submission tracks, and RWE alignment — is already shaping how experienced regulatory teams are planning submissions today. Treating the reauthorization as a future event rather than a present planning input is a common and avoidable mistake.

This article reflects publicly available information on the MDUFA VI negotiation process as of mid-2026, including FDA’s draft commitment letter posted July 7, 2026. Terms remain subject to change through the public comment period and congressional reauthorization process. This is intended for general regulatory and educational purposes and does not constitute regulatory or legal advice.